Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00694642

Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis (PROGENITOR)

Safety and Efficacy of Transendocardial Injection of Autologous Endothelial Progenitor Cell CD 133 for Therapeutics Angiogenesis

Sponsor: Fundación Mutua Madrileña

Conditions Coronary Artery Disease Refractory Angina

Interventions Selected CD 133+ cells

Updated 5 times since 2017 Last updated: Aug 4, 2013 Started: May 31, 2008 Primary completion: May 31, 2009 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Coronary Artery Disease and Refractory Angina, this trial is completed. The trial is conducted by Fundación Mutua Madrileña and has accumulated 5 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación Mutua Madrileña
Pilar Jimenez Quevedo

Data source: Hospital San Carlos, Madrid

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madrid, Spain